Relapsing remitting multiple sclerosis

Active Ingredient: Teriflunomide

Indication for Teriflunomide

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Therapeutic intent: Curative procedure

Teriflunomide is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS).

For this indication, competent medicine agencies globally authorize below treatments:

14 mg once daily

For:

Dosage regimens

Oral, 14 milligrams teriflunomide, once daily.

Detailed description

In adults, the recommended dose of teriflunomide is 14 mg once daily.

Elderly population

Teriflunomide should be used with caution in patients aged 65 years and over due to insufficient data on safety and efficacy.

Dosage considerations

Teriflunomide can be taken with or without food.

For patients weighting >40 kg 14 mg once daily and for patients weighting ≤40 kg 7 mg once daily

For:

Dosage regimens

Regimen A: In case that patient weight is > 40 kg, oral, 14 milligrams teriflunomide, once daily.

Regimen B: In case that patient weight is ≤ 40 kg, oral, 7 milligrams teriflunomide, once daily.

Detailed description

In paediatric patients (10 years of age and above), the recommended dose is dependent on body weight:

Paediatric patients with body weight >40 kg: 14 mg once daily.
Paediatric patients with body weight ≤40 kg: 7 mg once daily.

Paediatric patients who reach a stable body weight above 40 kg should be switched to 14 mg once daily.

Dosage considerations

Teriflunomide can be taken with or without food.

Active ingredient

Teriflunomide
Teriflunomide is an immunomodulatory agent with anti-inflammatory properties that selectively and reversibly inhibits the mitochondrial enzyme dihydroorotate dehydrogenase (DHO-DH), which functionally connects with the respiratory chain. As a consequence of the inhibition, teriflunomide generally reduces the proliferation of rapidly dividing cells that depend on de novo synthesis of pyrimidine to expand. The exact mechanism by which teriflunomide exerts its therapeutic effect in MS is not fully understood, but this is mediated by a reduced number of lymphocytes. Read more about Teriflunomide

Related medicines

Summary of Product Characteristics (SPC) 2024: AUBAGIO Film-coated tablet

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.